Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Infectious disease antibodies bind viral envelope proteins or bacterial toxins for neutralization and infection studies. Sotrovimab, casirivimab and bamlanivimab bind the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Palivizumab and nirsevimab neutralize respiratory syncytial virus (RSV) by binding its fusion protein. Bezlotoxumab binds Clostridioides difficile toxin B, while raxibacumab and obiltoxaximab neutralize the protective antigen of anthrax toxin. Further antibodies target human immunodeficiency virus (HIV), influenza, hepatitis B virus and Ebola virus glycoproteins, as well as cytomegalovirus and BK virus.
Tepsababart is a humanized monoclonal antibody targeting staphylococcal clumping factor A. This reagent exhibits specific binding to the clumping factor, facilitating studies on the pathogenesis of staphylococcal infections. It is a valuable tool for researchers investigating antibacterial mechanisms and developing therapeutic strategies against Staphylococcus aureus.
Out of stock
All 3 sizes
Synonyms: BJT-778
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody specifically targeting hepatitis B surface antigen (HBsAg). This reagent exhibits significant antiviral activity by neutralizing and eliminating both hepatitis B virus (HBV) and hepatitis D virus (HDV), as well as reducing HBsAg-containing subviral particles. Brelovitug is applicable in research related to HDV and HBV infections, chronic hepatitis delta (CHD), and chronic hepatitis B (CHB).
Out of stock
All 3 sizes
Potravitug is a humanized IgG1-κ monoclonal antibody that specifically targets the major capsid protein VP1 of BK polyomavirus (BKV). This reagent is crucial for investigating BKV-related pathologies, particularly in the context of BKV-induced nephropathy following organ transplantation. Its ability to selectively bind to VP1 facilitates research into therapeutic strategies and the immune response associated with BKV infections.
Out of stock
All 3 sizes
Calpurbatug is a human IgG1 monoclonal antibody specifically designed to bind members of the bacterial DNABII protein family, key structural components involved in the stability of bacterial biofilms. This antibody is functionally equivalent to anti-human monoclonal TRL1068 and carries a γ1 heavy chain. By targeting DNABII proteins, Calpurbatug disrupts the biofilm matrix and facilitates enhanced antimicrobial susceptibility, making it a valuable tool in bacterial pathogenesis studies and anti-biofilm therapeutic research.
Synonyms: Anti-Human SARS-CoV-2
Bamlanivimab is a fully human monoclonal antibody targeting the spike protein of SARS-CoV-2. It was the first anti-COVID-19 antibody to receive Emergency Use Authorization (EUA) from the U.S. FDA. Bamlanivimab binds to the receptor-binding domain (RBD) of the spike protein, neutralizing viral entry into host cells. It is a valuable tool for research on viral infection mechanisms, therapeutic neutralization, and emerging variant resistance.
Synonyms: MEDI 493
Palivizumab (MEDI 493) is a humanized IgG1 monoclonal antibody that targets the F protein of respiratory syncytial virus (RSV), a major cause of severe respiratory infections in infants and immunocompromised individuals. Palivizumab inhibits RSV fusion and entry into host cells, making it a critical research reagent for studying RSV pathogenesis, prophylaxis, and antibody-based antiviral strategies.
Synonyms: c4G7-N
Larcaviximab (c4G7-N) is a chimeric IgG1κ monoclonal antibody that targets the glycoprotein of the Ebola virus. It is designed to neutralize viral entry and fusion, and serves as a valuable research tool for investigating Ebola virus pathogenesis, antibody-based viral neutralization, and therapeutic antibody development against filoviruses.
Synonyms: CT-P59
Regdanvimab (CT-P59) is a fully human monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, preventing viral entry by blocking ACE2 interaction. It is widely used in COVID-19 research, including viral neutralization, variant efficacy assessment, and therapeutic antibody development.
Synonyms: KBPA101
Panobacumab (KBPA101) is a fully human monoclonal antibody of the IgM/κ class, produced through the immortalization of human B lymphocytes. This antibody specifically targets the lipopolysaccharide (LPS) O polysaccharide found on serotype O11 of Pseudomonas aeruginosa. Panobacumab is designed for high specificity and efficacy in recognizing this bacterial antigen, making it an invaluable tool for research into bacterial pathogenesis and immune response.
Vebanvibart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target SARS-CoV-2. For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control. This specificity and isotype make Vebanvibart suitable for research focused on viral pathogenesis and immune response to SARS-CoV-2.
Gacovetug is a chimeric antibody designed as a dimer type, specifically targeting the FaeG adhesin of F4+ enterotoxigenic Escherichia coli (ETEC). It features a variable heavy chain-human constant region (VH-h-CH2-CH3-CHS) architecture, making it highly specific for its bacterial target. This antibody is pivotal for research focused on the pathogenesis and immune response to ETEC infections, providing a valuable tool for the development of therapeutic strategies and diagnostic applications.
Synonyms: REGN2222
Suptavumab (REGN2222) is a human monoclonal antibody designed to specifically bind to and inhibit a conserved epitope on both the A and B subtypes of Respiratory Syncytial Virus (RSV). This antibody is utilized primarily in the investigation of RSV infections, providing a valuable tool for researchers studying the virus's pathogenesis and potential therapeutic interventions.
Synonyms: Anti-C. difficile Toxin A Recombinant Antibody
Actoxumab is a recombinant monoclonal antibody specifically designed to neutralize Clostridium difficile toxin A (TcdA). By binding to TcdA, Actoxumab effectively prevents the toxin's deleterious effects on the intestinal wall and mitigates the associated inflammatory responses. This antibody is particularly noted for its synergistic action when used in conjunction with Bezlotoxumab, which targets Clostridium difficile toxin B (TcdB). Together, these antibodies provide a comprehensive approach to managing the effects of both major C. difficile toxins. Actoxumab is valuable in research focused on the pathogenesis and treatment of C. difficile infections.
Atidortoxumab is a human IgG1κ monoclonal antibody specifically designed to target and neutralize Staphylococcus aureus alpha toxin. This antibody plays a crucial role in mitigating the cytotoxic effects induced by the alpha toxin, thereby contributing to the study of bacterial pathogenesis and the development of therapeutic strategies against Staphylococcus aureus infections.
Synonyms: MLTA3698A; RG7415; PRO283698
Pateclizumab (MLTA3698A) is a humanized monoclonal antibody specifically targeting lymphotoxin α (LTα), a cytokine transiently expressed on activated B and T cells, including Th1 and Th17 subsets. These cells play a critical role in the pathogenesis of rheumatoid arthritis (RA), making Pateclizumab a valuable tool for research into the mechanisms of this disease and potential therapeutic interventions.
Enibarcimab is a humanized murine monoclonal immunoglobulin G1 (IgG1) antibody designed for potential application in the research of acute heart failure, COVID-19 infections, and septic shock. This antibody targets specific antigens associated with these conditions, offering a valuable tool for detailed study and potential therapeutic development.
Traxivitug is a human IgG1 λ2 monoclonal antibody designed to target and neutralize BK virus (BKV). For accurate experimental control, it is recommended to use Human IgG1 λ2, Isotype Control.
Synonyms: REGN10987
Imdevimab (REGN10987) is a human monoclonal antibody designed specifically to target the SARS-CoV-2 virus responsible for COVID-19. Although it demonstrates limited efficacy against emerging COVID-19 variants, when used in conjunction with Casirivimab, Imdevimab has been shown to significantly reduce viral load and enhance disease outcomes. This combination therapy is pivotal for managing viral replication and improving patient response during treatment.
Synonyms: CR4098
Foravirumab (CR4098) is a monoclonal antibody specifically targeting antigenic site III of the rabies virus glycoprotein. This antibody is designed for precise binding to the rabies virus, facilitating further research into viral mechanisms and potential therapeutic interventions.
Synonyms: VIR 7831
Sotrovimab (VIR 7831) is a human IgG1κ monoclonal antibody designed to target and neutralize a broad range of sarbecoviruses, including SARS-CoV-2 and SARS-CoV-1. This antibody is derived from S309, a precursor known for its potent neutralizing capabilities. Sotrovimab features an extended half-life and enhanced bioavailability, particularly within the respiratory mucosa. Its mechanism of action facilitates the clearance of virus-infected cells and is effective in preventing the progression of COVID-19 when administered early in the disease course. This makes Sotrovimab a valuable tool in therapeutic interventions against COVID-19 and related coronavirus infections.
Docaravimab is a monoclonal antibody specifically designed to target the G-III epitope of the Evelyn-Rockitniki-Abelseth (ERA) glycoprotein ectodomain. This antibody is utilized primarily in the study of Rabies, facilitating advanced research into the virus's pathogenesis and immune evasion mechanisms. Docaravimab serves as a vital tool for researchers aiming to understand and potentially mitigate the effects of the Rabies virus at the molecular level.
Synonyms: MHAA4549A; RG7745
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody engineered to target the influenza A virus (IAV) with high specificity. It binds to the highly conserved stem region of the IAV hemagglutinin protein. This interaction inhibits hemagglutinin maturation and blocks hemagglutinin-mediated membrane fusion within the intranucleosome. Gedivumab is an essential tool for research in IAV infection disease studies, offering potential insights into viral entry mechanisms and the development of antiviral therapies.
Synonyms: SARS-CR3022; SARS-CoV-2 Antibody-CR3022
Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody produced in CHO cells. This antibody specifically binds to the S1 domain of the Spike protein present in both SARS-CoV and SARS-CoV-2, offering potential utility in the study of viral mechanisms and therapeutic development against COVID-19.
Synonyms: GC1102
Lenvervimab (GC1102) is a recombinant human immunoglobulin of the IgG1 subtype, specifically designed for the study of Hepatitis B virus (HBV) infections. This monoclonal antibody targets key antigens associated with HBV, making it a valuable tool for researchers investigating the pathogenesis, immune response, and potential therapeutic interventions for Hepatitis B.
Synonyms: BRII-198
Romlusevimab (BRII-198) is a recombinant human IgG1 monoclonal antibody designed to specifically neutralize the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This targeted mechanism of action facilitates the inhibition of viral entry into host cells, offering potential therapeutic benefits in the treatment and prevention of COVID-19. Romlusevimab’s specificity and neutralizing capability make it a valuable tool in coronavirus research and therapeutic development.
